- Home
- PCVX vs BIO Comparison
PCVX vs BIO Comparison
Compare PCVX & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCVX
- BIO
- Stock Information
- Founded
- PCVX 2013
- BIO 1952
- Country
- PCVX United States
- BIO United States
- Employees
- PCVX N/A
- BIO N/A
- Industry
- PCVX Biotechnology: Pharmaceutical Preparations
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- PCVX Health Care
- BIO Industrials
- Exchange
- PCVX Nasdaq
- BIO Nasdaq
- Market Cap
- PCVX 4.0B
- BIO 7.7B
- IPO Year
- PCVX 2020
- BIO N/A
- Fundamental
- Price
- PCVX $44.57
- BIO $336.12
- Analyst Decision
- PCVX Strong Buy
- BIO Strong Buy
- Analyst Count
- PCVX 8
- BIO 4
- Target Price
- PCVX $114.17
- BIO $333.50
- AVG Volume (30 Days)
- PCVX 1.8M
- BIO 227.9K
- Earning Date
- PCVX 11-05-2025
- BIO 10-29-2025
- Dividend Yield
- PCVX N/A
- BIO N/A
- EPS Growth
- PCVX N/A
- BIO N/A
- EPS
- PCVX N/A
- BIO 11.49
- Revenue
- PCVX N/A
- BIO $2,554,200,000.00
- Revenue This Year
- PCVX N/A
- BIO $2.05
- Revenue Next Year
- PCVX N/A
- BIO $2.86
- P/E Ratio
- PCVX N/A
- BIO $29.25
- Revenue Growth
- PCVX N/A
- BIO N/A
- 52 Week Low
- PCVX $27.66
- BIO $211.43
- 52 Week High
- PCVX $116.00
- BIO $387.99
- Technical
- Relative Strength Index (RSI)
- PCVX 67.31
- BIO 69.25
- Support Level
- PCVX $41.24
- BIO $326.64
- Resistance Level
- PCVX $43.45
- BIO $322.29
- Average True Range (ATR)
- PCVX 1.77
- BIO 9.86
- MACD
- PCVX -0.22
- BIO 3.22
- Stochastic Oscillator
- PCVX 84.58
- BIO 86.16
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.